ST Pharm Co.,Ltd. (KOSDAQ:237690)

Market Cap	2.59T
Revenue (ttm)	318.32B
Net Income (ttm)	36.89B
Shares Out	20.70M
EPS (ttm)	1,795.21
PE Ratio	69.63
Forward PE	42.35
Dividend	500.00 (0.39%)
Ex-Dividend Date	Dec 27, 2024

Volume	194,277
Average Volume	221,734
Open	126,000
Previous Close	127,500
Day's Range	122,400 - 126,400
52-Week Range	66,600 - 131,100
Beta	0.25
RSI	72.35
Earnings Date	Feb 5, 2026

About ST Pharm

ST Pharm Co.,Ltd., provides manufacturing services for active pharmaceutical ingredient and intermediate. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical research and development solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1983
• Employees: 655
• Stock Exchange: KOSDAQ
• Ticker Symbol: 237690

Financial Performance

In 2024, ST Pharm's revenue was 273.75 billion, a decrease of -3.94% compared to the previous year's 284.99 billion. Earnings were 34.71 billion, an increase of 77.27%.